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Abstract
Background: Regulations on medicinal products for paediatric use require that
pharmacokinetics and safety be characterized specifically in the paediatric population.
A previous study established that a 10-mg dose of bilastine in children aged 2 to
<12 years provided an equivalent systemic exposure as 20 mg in adults. The current
study assessed the safety and tolerability of bilastine 10 mg in children with allergic
rhinoconjunctivitis and chronic urticaria.
Methods: In this phase III, multicentre, double-blind study, children were randomized
to once-daily treatment with bilastine 10-mg oral dispersible table (n = 260) or placebo
(n = 249) for 12 weeks. Safety evaluations included treatment-emergent adverse events
(TEAEs), laboratory tests, cardiac safety (ECG recordings) and somnolence/sedation
using the Pediatric Sleep Questionnaire (PSQ).
Results: The primary hypothesis of non-inferiority between bilastine 10 mg and placebo
was demonstrated on the basis of a near-equivalent proportion of children in each
treatment arm without TEAEs during 12 weeks’ treatment (31.5 vs. 32.5%). No
clinically relevant differences between bilastine 10 mg and placebo were observed from
baseline to study end for TEAEs or related TEAEs, ECG parameters and PSQ scores.
The majority of TEAEs were mild or moderate in intensity. TEAEs led to discontin-
uation of two patients treated with bilastine 10 mg and one patient treated with placebo.
Conclusions: Bilastine 10 mg had a safety and tolerability profile similar to that of
placebo in children aged 2 to <12 years with allergic rhinoconjunctivitis or chronic
urticaria.
Allergic rhinoconjunctivitis and chronic urticaria are common
conditions in young children (<12 years) and carry a large
burden of disease (1, 2). Allergic symptoms frequently interfere
with a child’s ability to participate in daily activities and
disrupt normal sleeping patterns, causing emotional distress
and impacting negatively on learning and cognition (1, 3). This
can lead to major dysfunction within the family unit and
substantially impair the quality of life of the affected child and
other family members.
Second-generation H1 antihistamines are treatment of
choice for allergic rhinoconjunctivitis and chronic urticaria in
children (4, 5). Agents currently authorized for use in children
aged 2–11 years include cetirizine, desloratadine (1 year of
age), levocetirizine, loratadine and rupatadine (6–9). Given the
differences between second-generation H1 antihistamines in
terms of their biotransformation, transport and elimination (7),
and general age-related differences among children in their
ability to absorb, transform, metabolize and excrete medica-
tions (10), a need remains for effective options to treat chronic
allergic conditions in young children.
Bilastine is a second-generation oral H1 antihistamine
approved for use in several world regions at a once-daily dose
of 20 mg for symptomatic treatment of allergic rhinoconjunc-
tivitis and urticaria in adults and adolescents (≥12 years of
age). In these indications, bilastine has been shown to have an
efficacy similar to that of other second-generation oral H1
antihistamines and an excellent safety profile (11–14). To date,
there has been no evidence of sedative or cardiotoxic effects
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with bilastine in clinical trials or post-marketing experience (15,
16). Bilastine’s high selectivity for H1 receptors (17), limited
passage across the blood–brain barrier (18) and negligible
metabolism (19) may confer safety and tolerability advantages
over other oral second-generation H1 antihistamines used to
treat these conditions.
Although regulations on medicinal products for paediatric
use allow for the extrapolation of much of the data generated
during studies in adults to paediatric populations, exceptions
are pharmacokinetic data (to establish appropriate dosing) and
safety data. Previously, a paediatric pharmacokinetic study
(protocol BILA-3009/PED – EudraCT No.: 2009-012013-22)
established that a 10-mg dose of bilastine in children aged 2 to
<12 years provided an equivalent systemic exposure as a 20 mg
dose in adults (20). The aim of this study was to assess the
safety and tolerability of bilastine 10 mg once daily in children
aged 2–11 years with allergic rhinoconjunctivitis or chronic
urticaria.
Methods
This phase III, double-blind, randomized, placebo-controlled,
parallel-group study was conducted between March 2013 and
July 2014 at 20 centres in Argentina, Croatia, Hungary,
Poland, Portugal and Spain. Eligibility criteria were boys and
girls aged 2–11 years with a documented history of allergic
rhinoconjunctivitis or chronic urticaria and with clinical
symptoms at study entry. For patients with allergic rhinocon-
junctivitis, a positive skin prick test/RAST for at least one
allergen was necessary. Results of a 12-lead electrocardiogram
(ECG) had to be within acceptable limits, with QTc interval
values after Fridericia’s correction within normal limits
(<440 msec).
Exclusion criteria were as follows: hypersensitivity to H1
antihistamines (including bilastine) or benzimidazoles; any
concurrent clinical condition or relevant history of renal,
hepatic, gastrointestinal tract, cardiovascular, respiratory,
haematological, endocrine or neurological diseases; and clin-
ically relevant abnormal laboratory values indicative of phys-
ical illness. Intake of the following medications was not
allowed within 7 days (or otherwise noted) prior to random-
ization: oral corticosteroids; loratadine/desloratadine (10 days)
or other systemic antihistamines (3 days); antileukotrienes;
delayed-release corticosteroids (3 months); ketotifen (2 weeks);
macrolide antibiotics and imidazolic antifungals (systemic);
anticholinergics; investigational medication or antibodies.
Regularly scheduled immunotherapy was permitted through-
out the study except for 24 h before and 24 h after the first
dose of study medication.
Six visits were scheduled: screening, baseline, week 4, week
8, week 12 (end of treatment) and a post-treatment follow-up
at week 16. Screening assessments included patient history,
demographic data, physical examination, 12-lead ECG and a
blood sample for laboratory tests. Baseline evaluations
included physical examination, 12-lead ECG, adverse events
and somnolence/sedation assessment. These same assessments
were repeated at weeks 4, 8 and 12, at which times treatment
compliance, concomitant medication and the use of rescue
medication were also evaluated. Additional activity at week 12
was to take a blood sample for laboratory tests. The safety
follow-up at week 16 involved a physical examination, adverse
events assessment, somnolence/sedation assessment and
recording of concomitant medication. Patients who discontin-
ued the study at any time during the 12-week treatment period
were asked to attend an early termination visit in which all
activities scheduled for the week 12 visit were conducted.
Study treatments were allocated according to a pre-
established randomization list by age strata (2 to <6 years, 6
to <9 years, 9 to <12 years) created by the sponsor, using a
random design by blocks. Bilastine and placebo were matched
in pharmaceutical form and had identical packaging to
maintain blinding.
Abilastine 10-mgoral dispersible tablet (dissolved inwater for
children 2 to<6 years, and either swallowedor dissolved inwater
for children aged 6 to <12 years) or placebo was administered
once daily in the morning under fasting conditions (1 h before
breakfast or two hours after breakfast) for 12 weeks.
To limit the number of dropouts, occasional use of rescue
medication was allowed in the form of short-term topical
decongestants (eye or nose), corticosteroids or antihistamines
for rhinoconjunctivitis, or short-term topical corticosteroids
for urticaria.
In accordance with guidance from the Paediatric Committee
of the European Medicines Agency, the primary analysis
variable was the proportion of children in each treatment
group without treatment-emergent adverse events (TEAEs)
during the course of the study.
Secondary variables included: the proportion of children
with related TEAEs during the course of the study; incidence of
TEAEs by System Organ Class and Preferred Term; laboratory
blood tests performed at baseline and the end of treatment;
assessment of cardiac safety by ECG at each visit; assessment
of somnolence/sedation with the Pediatric Sleep Questionnaire
(PSQ).
The study was performed in strict compliance with the
International Conference on Harmonisation Good Clinical
Practice Guidelines and the most recent revision of the
Declaration of Helsinki (Seoul 2008). The study protocol was
approved by ethics committees of all participating centres in
accordance with local regulatory requirements. Parent(s)/
guardian provided written consent for the child to participate
in the study.
Statistical analysis
Under the assumption that 80% of patients in each treatment
group would experience at least one TEAE during the course of
the study, and using a one-sided 0.025 significance level and a
10% delta, it was calculated that 504 patients (252 per
treatment group) were required to achieve a power of 80%.
Non-inferiority was to be accepted if the upper limit of the two-
sided 95% confidence interval (CI) for the difference in the
incidence of TEAEs (bilastine minus placebo) was less than
10%.
Statistical analysis was performed using SAS version 9.2
(Cary, NC, USA).
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Statistical significance was assessed for two-sided probability
values <0.05 unless otherwise specified (e.g. when checking
non-inferiority). Missing values were not considered for
statistical calculations, and no imputations were performed
to replace missing values. Although the study was not powered
for a stratified analysis, descriptive results of TEAEs were
provided by age strata.
Quantitative variables were described by the number of
subjects, means, standard deviations, maximum and minimum
values and quartile values. Qualitative variables were described
by frequency and percentage.
The somnolence/sedation questionnaire was assessed by an
analysis of covariance (ANCOVA) model, with treatment as the
main factor and baseline values as covariates.
Secondary categorical variables were assessed by means of
the chi-squared test, or the Fisher’s exact test, if applicability
conditions were not met.
Results
Of 537 children screened, 509 were randomized to either
bilastine 10 mg (n = 260) or placebo (n = 249). All random-
ized patients received study medication and comprised the
safety population. Twelve patients in each treatment group
were withdrawn before the end of the study (Fig. 1). TEAEs
leading to discontinuation were atopic dermatitis (n = 1) and
loss of consciousness, dizziness and fatigue (n = 1) in the
bilastine 10-mg group and urticaria (n = 1) in the placebo
group.
Treatment groups were well matched at baseline for demo-
graphic and other characteristics (Table 1). The mean age of
the patient sample was 7.5  2.4 years, the proportion of male
patients was 62.5%, and 93% of the population were
Caucasian. Time since diagnosis was approximately 3.5 years,
and the majority of patients had allergic rhinoconjunctivitis.
Compliance, as assessed by tablet count, was 98.5% in the
bilastine 10-mg group and 98.6% in the placebo group. Similar
proportions of patients in each group required rescue medica-
tion (24.6 and 20.1%, respectively).
Safety
Overall, 31.5% of patients (n = 82) in the bilastine 10-mg
group and 32.5% of patients (n = 81) in the placebo group
were without TEAEs during the course of the study, for a
treatment difference of 0.99% (95% CI: 9.10, 7.10) in the
primary variable (Fig. 2). No statistically significant differ-
ences were found between treatment groups for incidences of
TEAEs (Fig. 2) or related TEAEs (Fig. 3) in the population
overall or by age subgroup.
The most commonly reported TEAEs (frequency ≥5% in
any treatment group) were headache, cough, pharyngitis,
allergic conjunctivitis, nasopharyngitis and pyrexia (Table 2).
Related TEAEs reported by more than one patient in either
the bilastine or placebo group were allergic conjunctivitis (5
vs. 6 events), upper abdominal pain (1 vs. 3 events),
vomiting (0 vs. 2 events), rhinitis (3 vs. 4 events), headache
(6 vs. 6 events), somnolence (0 vs. 2 events), nasal congestion
(0 vs. 2 events), allergic rhinitis (0 vs. 8 events), sneezing (0
vs. 9 events) and urticaria (2 vs. 2 events). The majority of
related TEAEs were mild to moderate in intensity (92% for
bilastine 10 mg and 86% for placebo). Analysis of TEAEs
by System Organ Class (frequency ≥2% in the overall
n = 537
Patients included
n = 509
Patients randomised
n = 509
Patients who received study medication
n = 28
Screen failures
Reasons:
• Withdrawal consent (14)
• Inclusion/Exclusion criteria (6)
• Prohibited medication (2)
• Other (6)
n = 260
Bilastine 10 mg
n = 249
Placebo
n = 248
Completed
n = 12
Withdrawn
n = 237
Completed
n = 12
Withdrawn
• Voluntary withdrawal (1)
• Inclusion/Exclusion criteria (1)
• Adverse event (3)
• Treatment failure (1)
• Poor compliance to protocol (1)
• Prohibited medication (3)
• Lost to follow-up (1)
• Other (1)
• Voluntary withdrawal (1)
• Inclusion/Exclusion criteria (1)
• Adverse event (2)
• Treatment failure (3)
• Poor compliance to protocol (1)
• Prohibited medication (3)
• Other (1)
Figure 1 Patient disposition.
Table 1 Demographic and other baseline characteristics: safety
population
Variable
Bilastine 10 mg
(n = 260)
Placebo
(n = 249)
Age (years), mean (SD) 7.5 (2.4) 7.4 (2.5)
Age categories
2 to <6 years, n (%) 58 (22.3) 58 (23.3)
6 to <9 years, n (%) 105 (40.4) 95 (38.2)
9 to <12 years, n (%) 97 (37.3) 96 (38.6)
Gender (male), n (%) 163 (62.7) 155 (62.2)
Race (Caucasian), n (%) 244 (93.8) 234 (94.0)
Height (cm), mean (SD) 129.1 (15.9) 128.8 (16.8)
Weight (kg), mean (SD) 30.3 (11.5) 30.5 (12.1)
Body mass index
(kg/m2), mean (SD)
17.6 (3.3) 17.7 (3.3)
Time since diagnosis
(years), mean (SD)
3.6 (2.5) 3.5 (2.6)
Type of diagnosis
Allergic
rhinoconjunctivitis, n (%)
252 (96.9) 227 (91.2)
Chronic urticaria, n (%) 8 (3.1) 22 (8.8)
SD, standard deviation.
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population) showed no statistically significant differences
between treatment groups according to body system.
There were no deaths during the study. Of 14 serious
TEAEs reported in 11 patients (two events in two patients
treated with bilastine 10 mg, 12 events in nine patients
treated with placebo), none was considered to be related to
treatment.
There were no clinically and/or statistically relevant differ-
ences between bilastine 10 mg and placebo for vital signs
(systolic and diastolic blood pressure, heart rate and body
temperature), clinical laboratory values (except for one patient
with elevated transaminases at screening who was withdrawn
from the study after one dose of bilastine 10 mg), ECG
parameters or physical examination.
PSQ scores for somnolence/sedation decreased slightly from
baseline to week 12 in both the bilastine 10-mg and placebo
groups (Fig. 4). Between-group differences were not statisti-
cally significant for the total score or for scores in the
individual domains.
Discussion
Given the difficulties and ethical considerations associated with
performing clinical trials in children (21), a common approach
has been to utilize data generated in adults and adjust the dose
according to a child’s weight. However, as children have
developmental and physiological characteristics distinct from
adults and respond differently to medications (10), this practice
is now considered to be wholly inappropriate. In recent times,
legislation has been enacted to encourage the development of
medicines for children and to improve information about the
use of medicines in children (21, 22). As part of the bilastine
Paediatric Investigation Plan submitted to the European
Medicines Agency (EMA), this phase III, multicentre, double-
blind, randomized study was undertaken to assess the safety
and tolerability of bilastine 10-mg oral dispersible tablet
administered once daily for 12 weeks in children aged
2–11 years with allergic rhinoconjunctivitis or chronic urticaria.
The primary hypothesis of non-inferiority of bilastine 10 mg
with respect to placebo was demonstrated on the basis of a
near equivalent proportion of children in each treatment arm
without TEAEs during 12 weeks’ treatment (31.5% vs.
32.5%). Results for the primary analysis variable were
supported by all secondary safety variables. No meaningful
differences between treatment groups were observed from
baseline to study end for TEAEs or related TEAEs, vital signs,
ECG parameters and somnolence/sedation scores. The safety
and tolerability profiles of bilastine 10 mg and placebo were
Bilastine 10 mg
Children with any TEAE (%)
67.2
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70.7
69.5  
69.5
65.6
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68.5
20 40 60 80 100
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Figure 2 Children (%) with any
treatment-emergent adverse event
(TEAE) in the population overall and
by age range.
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496 Pediatric Allergy and Immunology 27 (2016) 493–498 ª 2016 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd.
Safety of bilastine 10 mg in children Novak et al.
similar across all three age strata (2 to <6 years, 6 to <9 years
and 9 to <12 years) and across a range of different climates in
participating countries from the Northern and Southern
Hemispheres.
The 12-week study duration was in accordance with EMA
guidelines for clinical development of medicinal products for
treatment of allergic rhinoconjunctivitis in children. Bilastine
thus joins cetirizine (23), levocetirizine (24, 25) and loratadine
(26) as second-generation H1 antihistamines approved for use
in paediatric patients for which long-term safety data are
available.
In terms of limitations, for safety and regulatory reasons, the
bilastine dose was set at 10 mg once daily including in children
with chronic urticaria. As such, no information was obtained
on dose escalation in young children. Greater efficacy with
fourfold updosing of bilastine (i.e. 80 mg), without an increase
in sedation, has been demonstrated in adults with cold contact
urticaria (27); whether the same holds true for young children
remains to be determined. The hypothesis of non-inferiority
between bilastine and placebo was based on the assumption
that 80% of patients would experience at least one TEAE
during the 12-week treatment period. Although only 70% of
patients experienced a TEAE, the low attrition rate meant that
the sample size was still sufficient to confirm non-inferiority
between bilastine 10 mg and placebo.
Conclusions
On the basis of a confirmed primary hypothesis of non-
inferiority between bilastine 10 mg and placebo with respect to
the proportion of children without TEAEs, and the similar
safety and tolerability profile of bilastine 10 mg and placebo,
bilastine 10 mg can be considered a suitable treatment option
for children aged 2–11 years with allergic rhinoconjunctivitis
or chronic urticaria.
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Figure 4 Assessment of somnolence/sedation from baseline (D0) to
week 12 (W12) according to global scores on the four domains of the
Pediatric Sleep Questionnaire: sleeping-related breathing disorder
(SRBD), daytime sleepiness, snoring and inattention.
Table 2 Most frequent treatment-emergent adverse events (≥5%
frequency); safety population
Adverse event
Bilastine 10 mg (n = 260)
Events/Patients (%)
Placebo (n = 249)
Events/Patients (%)
Headache 48/30 (11.5) 45/26 (10.4)
Cough 29/23 (8.8) 32/22 (8.8)
Pharyngitis 27/25 (9.6) 18/16 (6.4)
Allergic
conjunctivitis
25/24 (9.2) 21/19 (7.6)
Nasopharyngitis 38/24 (9.2) 19/17 (6.8)
Pyrexia 16/16 (6.2) 38/23 (9.2)
Allergic rhinitis 20/13 (5.0) 28/21 (8.4)
Bronchitis 12/10 (3.8) 15/14 (5.6)
Viral infection 12/10 (3.8) 18/16 (6.4)
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